Effect of Perioperative β-Blockers on Pulmonary Complications among Patients with Chronic Obstructive Pulmonary Disease Undergoing Lung Resection Surgery

Table 1

Clinical characteristics of patients that received perioperative β-blockers in comparison to those that did not. Data are expressed as the number of patients in each group.

Clinical variable (%)	-blockers ()	No -blockers ()	value
Age >60 years	175 (85.4%)	222 (70.5%)	0.0001
Male sex	112 (54.6%)	130 (41.3%)	0.003
FEV1% <50	16 (7.8%)	26 (8.3%)	n.s.
DLCO% <50	18 (8.9%)	32 (10.3%)	n.s.
Prior history
Asthma	6 (2.9%)	15 (4.8%)	n.s.
Cardiac disease	143 (69.8%)	113 (35.9%)	<0.0001
Chronic renal insufficiency	5 (2.5%)	4 (1.3%)	n.s.
Diabetes mellitus	27 (13.2%)	25 (7.9%)	n.s.
Smoking within 6 months	71 (34.8%)	127 (40.3%)	n.s.
Extent of lung resection
Sublobar	48 (23.4%)	82 (26.0%)	n.s.
Lobectomy	133 (64.9%)	200 (63.5%)	n.s.
Bilobectomy/pneumonectomy	24 (11.7%)	33 (10.5%)	n.s.
Complications
COPD exacerbation	11 (5.4%)	20 (6.4%)	n.s.
Respiratory failure	7 (3.4%)	10 (3.2%)	n.s.
Cardiac complication	18 (8.8%)	17 (5.4%)	n.s.
ICU transfer	12 (5.9%)	15 (4.8%)	n.s.
Death (30 d)	4 (2.0%)	1 (0.3%)	n.s.